InMed Pharmaceuticals INM Institutional Ownership

Updated Nov 6, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM) was reported as a holding by 18 institutional investors in 13F filings for the quarter ended June 30, 2026.

• These investors held 50.52% of InMed Pharmaceuticals' outstanding shares at the end of Q2 2026, up from 7.89% in Q1 2026.
• Total holdings of InMed Pharmaceuticals shares rose 744.86% from Q1 2026, and the number of holders rose 500.00% from Q2 2025.
• Looking at the 18 holders of INM individually, 13 added to their positions, 3 reduced their stakes and 2 left their positions unchanged.
• In total, institutional investors held 269.76K shares of InMed Pharmaceuticals at the end of Q2 2026, up 237.83K from the prior quarter and up 268.92K from a year earlier.
• As of June 30, 2026, the biggest holder of InMed Pharmaceuticals was ADAR1 Capital Management, LLC with 80K shares, or 14.98% of shares outstanding.
• Holders that trimmed the most shares of InMed Pharmaceuticals in Q2 2026 while keeping a position were Sabby Management, LLC (-17.53K shares), Citadel Advisors LLC (-2.09K shares) and Two Sigma Securities, LLC (-777 shares).
• Per Business Quant data, the 10 largest holders of InMed Pharmaceuticals at the end of Q2 2026 were ADAR1 Capital Management, LLC (80K shares), Vivo Capital, LLC (79.84K shares), Squadron Capital Management LLC (32.5K shares), Ikarian Capital, LLC (24.5K shares), Ursa Fund Management, LLC (12.58K shares), Montanova Capital, LLC (10K shares), Boothbay Fund Management, LLC (7.42K shares), Sabby Management, LLC (4.5K shares), Jane Street Group, LLC (4.31K shares) and Venrock Adviser, LLC (3.27K shares).